Drug intelligence / Profile preview

HSV 2 Formulation 2

Development stage: Unknown
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

"HSV 2 Formulation 2" is an experimental vaccine formulation developed by Sanofi Pasteur, currently undergoing clinical evaluation for the prevention and management of genital herpes caused by Herpes Simplex Virus type 2 (HSV-2). It is one of several formulations being tested in the HSV15 trial, which aims to assess the safety and efficacy of these vaccine candidates in reducing genital herpes outbreaks and viral shedding. The specific antigenic components and adjuvants of this particular formulation are not publicly detailed, but as a vaccine, its intended mechanism involves stimulating the host's immune system to mount a protective response against HSV-2.

Other names: HSV formulation 2

Beyond the preview

Go deeper on HSV 2 Formulation 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HSV 2 Formulation 2.

Explore the full profile